AR and thyroid cancer: Previous work suggested that AR activation attenuates Programmed Death Receptor Ligand 1 (PD-L1) expression in AR-responsive thyroid cancer cell lines, potentially though NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling, enhancing the susceptibility of cells to immune destruction [24].